|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHST5 |
Gene summary for CHST5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHST5 | Gene ID | 23563 |
| Gene name | carbohydrate sulfotransferase 5 | |
| Gene Alias | I-GlcNAc-6-ST | |
| Cytomap | 16q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9GZS9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23563 | CHST5 | Pat01-B | Human | Stomach | GC | 2.52e-26 | 5.15e-01 | 0.5754 |
| 23563 | CHST5 | Pat02-B | Human | Stomach | GC | 8.40e-04 | 1.38e-01 | 0.0368 |
| 23563 | CHST5 | Pat03-B | Human | Stomach | GC | 1.68e-17 | 3.77e-01 | 0.3693 |
| 23563 | CHST5 | Pat13-B | Human | Stomach | GC | 4.95e-07 | 2.42e-01 | 0.0555 |
| 23563 | CHST5 | Pat16-B | Human | Stomach | GC | 9.13e-06 | 2.23e-01 | 0.1918 |
| 23563 | CHST5 | Pat17-B | Human | Stomach | GC | 1.39e-14 | 4.04e-01 | 0.3109 |
| 23563 | CHST5 | Pat19-B | Human | Stomach | GC | 3.38e-03 | 1.54e-01 | 0.0826 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00067903 | Stomach | GC | sulfur compound metabolic process | 35/1159 | 339/18723 | 2.10e-03 | 2.10e-02 | 35 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHST5 | SNV | Missense_Mutation | rs761010831 | c.410G>A | p.Arg137Gln | p.R137Q | Q9GZS9 | protein_coding | tolerated(0.06) | benign(0.251) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CHST5 | SNV | Missense_Mutation | rs752681577 | c.1097G>A | p.Arg366His | p.R366H | Q9GZS9 | protein_coding | deleterious(0.03) | probably_damaging(0.932) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHST5 | SNV | Missense_Mutation | c.1226N>T | p.Ser409Leu | p.S409L | Q9GZS9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.715) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD | |
| CHST5 | insertion | In_Frame_Ins | novel | c.1155_1156insTCATGGAAAGCA | p.Ser385_Ala386insSerTrpLysAla | p.S385_A386insSWKA | Q9GZS9 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| CHST5 | SNV | Missense_Mutation | novel | c.299C>T | p.Thr100Ile | p.T100I | Q9GZS9 | protein_coding | deleterious(0.03) | benign(0.1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHST5 | SNV | Missense_Mutation | c.1171G>A | p.Asp391Asn | p.D391N | Q9GZS9 | protein_coding | tolerated(1) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CHST5 | SNV | Missense_Mutation | c.427N>C | p.Phe143Leu | p.F143L | Q9GZS9 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHST5 | SNV | Missense_Mutation | c.1231N>A | p.Asp411Asn | p.D411N | Q9GZS9 | protein_coding | tolerated_low_confidence(0.19) | benign(0.007) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CHST5 | SNV | Missense_Mutation | rs572591635 | c.340N>A | p.Val114Met | p.V114M | Q9GZS9 | protein_coding | deleterious(0.03) | probably_damaging(0.925) | TCGA-A6-6654-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
| CHST5 | SNV | Missense_Mutation | c.886N>A | p.Glu296Lys | p.E296K | Q9GZS9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |